Cancer prevention, occurrence and relapse are all about identifying risks. GERD can lead to Barrett’s Esophagus which can lead to Esophageal Cancer. The challenge of identifying cancer risk, in the case of esophageal cancer, is that life often gets in the way.
My point here is a simple, everyday scenario. Considering more than 60 million American adults suffer heartburn at least once a month and about 25 million American adults suffer daily from heartburn, it is logical to think that this group buys a proton pump inhibitor (PPI- Prilosec, Prevacid, Nexium, etc.) at their local drugstore.
After all, unless you live under a rock you know that PPI’s reduce heartburn, right? The easiest, quickest and cheapest way for you to feel better is a PPI, right? Unfortunately, in the world of cancer risks, short-term fixes can lead to long-term problems.
Could PPI’s have other potential side effects? Does the use of PPI’s lead to Barrett’s Esophagus?
While there is no definitive answer to this question, there is enough evidence that long-term use of PPI’s cause health problems.
Whether you have GERD, BE or EC, there are non-toxic therapies to help you feel better and reduce your risks of progressing from one stage to the next.
For more information on conventional, non-conventional, integrative cancer therapies, scroll down the page, post a question or comment and I will reply to you ASAP.
“The alarming increase of EAC by 600% for the past 25years suggests that BE has increased as well, as the latter represents the main risk factor for EAC (4–6). This emphasizes the importance of better understanding the causal process leading to intestinal metaplasia (BE) and suggests that a possible re-evaluation of the current protocol for the management and treatment of GERD and BE may be beneficial….
“CONCLUSIONS: In this population-based nested case-control study, use of NSAIDs, PPIs, low-dose aspirin or statins did not reduce the risk of HGD and OAC among patients with BO. These findings indicate that for an unselected group of patients with BO chemoprevention by use of drugs to reduce progression to HGD and OAC should not be directly considered as routine care.“
“Background: The association of long-term use of proton pump inhibitors (PPIs) with oesophageal adenocarcinoma has been poorly defined. Our aim was to assess the risk of oesophageal cancer assessing confounding by indication.
Methods: This population-based cohort study included all 796,492 adults exposed to maintenance therapy with PPIs in Sweden in 2005-2012. Standardised incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated to assess the risk of oesophageal adenocarcinoma (and squamous cell carcinoma as a comparison) among long-term PPI users relative to the corresponding background population. The different indications for maintenance PPI therapy were analysed separately.
Results: Among all individuals using maintenance PPI therapy, the overall SIR of oesophageal adenocarcinoma was 3.93 (95% CI 3.63-4.24). The SIRs of adenocarcinoma were increased also among individuals without gastro-oesophageal reflux disease who used PPIs for indications not associated with any increased risk of oesophageal adenocarcinoma. For example, the SIRs among participants using maintenance PPI therapy because of maintenance treatment with non-steroidal anti-inflammatory drugs and aspirin were 2.74 (95% CI 1.96-3.71) and 2.06 (95% CI 1.60-2.60), respectively. The SIRs of oesophageal squamous cell carcinoma were increased for most investigated indications, but to a lesser degree than for oesophageal adenocarcinoma.
Conclusion: In conclusion, the long term use of PPIs is associated with increased risk of oesophageal adenocarcinoma in the absence of other risk factors. Long term use of PPIs should be addressed with caution.